Is there a role for dose escalation beyond 50.4 Gy in neoadjuvant chemoradiation therapy for rectal cancer?
1 Answer
Mednet MemberInvited Expert
Radiation Oncology · Memorial Sloan-Kettering Cancer Center
Answered on
There are probably a variety of opinions about this, but there is no proven role for doses higher than 50.4 Gy. Doses between 50Gy and 60Gy have been studied extensively, including a PhII trial reported by RTOG that was negative for pCR endpoint with 59Gy, and there is no dose response within this r...
Join for free or sign in to see the full answer